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G
T
Searly-stage SCLC. In the absence of mediastinal nodal ex-
tension or remote metastatic disease, the addition of adju-
vant RT after sublobar resection does not improve overall
or cancer-specific survival. RT should be considered for pa-
tients who are unfit for any surgical resection.
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Dr Jessica Donington (New York, NY). Thoracic surgery has
been discounted for the treatment of SCLC since the 1970s and
1980s because of some randomized trials that lumped all of the
limited disease together, probably inappropriately. I think the
nicework Eric Vallieres did as part of the International Association
for the Study of Lung Cancer Lung Cancer Staging Project showed
us that for patients with SCLC without metastatic disease, both the
T stage and the N stage carry significant prognostic and therapeutic
implications. I congratulate you on this excellent work. In looking
at that, do we have to look at this as a review of SEER data? I have
actually never performed a SEER review, so maybe you can edu-
cate me as to some of the things we can and can’t take out of this.
When we look at the way the patients were staged in this series,
I’m assuming that we have both clinical and pathologic stages
that we are comparing between the radiation and the surgery
groups. Correct?
Dr DeCamp. SEER reports the use of surgery and reports down
to the histology of lymph nodes that are sampled, so in the surgery
group, obviously there is more precise staging than in the patients
with no resection, so they may have only a biopsy, as you saw in
Tables 1 and 2.
Dr Donington. So it would be comparing apples and oranges in
terms of survival. I guess the samemay also be true in that we don’t
really know about intention to treat and the use of sublobar versus
lobectomy or greater in treatment. I’m assuming the sublobars in
this series were probably performed in patients who could not
tolerate a lobectomy, or we just don’t have any information?
Dr DeCamp. We have no knowledge of the surgeon’s intent.
When we looked at segmentectomy versus wedge resection, the re-
sults didn’t seem any different. Likewise, if we lumped lobectomy,
bilobectomy, and pneumonectomy together, if we tried to split out
pneumonectomy, there was no difference in the data, but obvi-
ously, because it’s retrospective, there is a possibility for selection
bias.ery c September 2011
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SDrDonington.What kind of information does SEER provide in
terms of knowing about the radiation given? I know it doesn’t give
specifics about field, intensity, and such. Was it all thoracic radia-
tion or was some of this percutaneous coronary intervention?
Dr DeCamp. No, this was all thoracic radiation.
Dr Donington. Do we know about how much prophylactic cra-
nial irradiation was given to these patients? We know that signif-
icantly affects survival in this population.
Dr DeCamp. No, we don’t.
Dr Donington.Your work actually coincides with several other
reviews of the SEER database looking at surgical resection for
SCLC. The 3 reviews, yours, one from Yale, and one from
SUNY Downstate, have similar take-home messages: There really
is an important role for surgery. Some of the take-home message
regarding the use of adjuvant RT, though, was different. Can you
address the fact that those 2 studies actually found no impact
from the use of adjuvant RT, or in the SUNY review, a similar
kind of pattern to what we see in NSCLC, where with increasing
nodal status, perhaps adjuvant radiation makes sense.
Dr DeCamp. The difference among the 3 SEER reviews is that
we restricted ourselves to early stage, not limited stage, as the
oncologists like to speak of it, but T1N0, T2N0, and N1 cases.
The SUNYDownstate review, which is primarily written by radio-
therapists, makes the analogy to the PORT meta-analysis in
NSCLC; in that analysis, there was a detriment when radiation
was used in stage I disease, although it included some old radiation
from the 1970s, which may have been more detrimental, no benefit
for stage II, but a small survival benefit in stage III disease. We
have no patients with stage III in our series, and we are doing
this from the perspective of surgeons and clinicians.
Dr Donington. Did you see any difference in survival with ra-
diation between those with stage I and those with stage II?
Dr DeCamp.No, we didn’t. It seems that the patients derive no
additional benefit from the addition of radiation after surgery. As
you see from the curves, the P values are between .2 and .5, so
they are statistically similar and clearly inferior to any of the sur-
gical arms, which was surgery alone.
Dr Donington. My last question is speculative in nature. Do
you have any insight as towhy we saw that fairly dramatic increase
in the cases of small cell in 2004 and 2005?
DrDeCamp. I found that kind of interesting in an era when half
the American smoking population quit smoking in the last 30
years. Sowe have fewer active smokers. Small cell tends to be a dis-
ease of active smokers. I think a lot of it has to do with the increas-
ing utility of computed tomography scanning and finding more
tumors earlier, and that may be a prediagnosis or an overdiagnosis
bias, but as we think about NSCLC and SCLC, people die of these
diseases; they don’t die with these diseases. So I have a hard time
accepting the overdiagnosis bias argument. I don’t know why
we’re seeing so many more small cell cases, but it was curious
and consistent in the last 4 or 5 years of this review.
Dr Donington. I think it makes your article ever more
important.
Dr Raja Flores (New York, NY). Mac, I commend you on doing
a great job with the limited data that are presented in SEER. I think
this does add support to thoracic surgeons performing surgical
resection for SCLC. I have a quick question. With these patients
who underwent surgery, do you have any idea of the number ofThe Journal of Thoracic and Capatients who underwent preoperative mediastinoscopy? Is that
recorded at all in the SEER database?
Dr DeCamp. No. You just get a report of lymph nodes. You
don’t get a report of how they were obtained. So you get medias-
tinal or hilar lymph nodes. We can assume the hilar nodes were not
at mediastinoscopy.
Dr Mark Iannettoni (Iowa City, Iowa). Mac, I enjoyed your
article. This is the third time we’ve heard that surgery has value
for SCLC. In 1985 John Meyer presented it. Tom Shields has pre-
sented it in the past. Why do you think we just haven’t gotten
through to people yet that this is a valuable entity?
Dr DeCamp. I can only speculate that there are not multidisci-
plinary teams evaluating patients, and if you don’t see them and
you’re not involved, you won’t be at the table making the treatment
decisions. The SUNY Downstate review, which was primarily
written by radiation oncologists, and the current article will bring
this more into the consciousness, and with more multidisciplinary
evaluations being performed around the country, we’ll be back at
the table.
Dr Iannettoni. I think that’s the point. We need to get out of the
operating room and get to some of these conferences.
Dr Joe Putnam (Nashville, Tenn). I enjoyed the article and was
curious if this may reflect a more nihilistic approach of other spe-
cialists, such as medical or radiation oncology. These specialists
see patients with more advanced stage SCLC and may be reluctant
to have smaller SCLCs treated with resection as an initial treat-
ment modality.
The question I have is about diagnosis. Were you able to deter-
mine the percentage of patients who had a diagnosis preopera-
tively versus postoperatively? Many of these patients may have
a diagnosis made as a consequence of operations for a solitary
pulmonary nodule.
Dr DeCamp. From the SEER data, I know of no way to
discriminate or answer that question specifically.
Dr Putnam. From your data, the change over time may have
resulted in the increased use of computed tomography and other
diagnostic studies, as well as more availability of preoperative nee-
dle diagnosis. In those patients who had a diagnosis of SCLCmade
with needle diagnosis, the surgeon may never see them, even if
they have limited and resectable disease. It may be helpful to
partner with our radiologists in addition to our medical oncologists
to understand that these patients can be seen by a surgeon and
effectively treated.
Dr Stephen Yang (Baltimore, Md). As a follow-up to this,
maybe we can have a take-home message from all these article.
I’ll sort of plug Malcolm Brock’s article from 1997 from our insti-
tution, in which he showed that with platinum-based therapy these
days, surgery plus chemotherapy affords a 75% 5-year survival for
stage I disease. The take-home message now: The patient comes
in, small cell, preoperative diagnosis. What do you tell the tumor
board? In the second scenario, as Bill alluded to, the patient has
a lobectomy for a solitary nodule, and it comes back a small
cell. What is the decision point after that?
Dr DeCamp. Thank you, Steve. I have to take my hat off to
Dave Sugarbaker if he’s in the audience because he taught me
that you evaluate a solitary pulmonary nodule, and if it is small
cell and the mediastinum is negative, take it out. You do the lobec-
tomy. Treat it like you do lung cancer. If this person clearly needsrdiovascular Surgery c Volume 142, Number 3 545
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a mediastinoscopy and lobectomy on the basis of what we learned
this morning or a goodmediastinal sampling or radical mediastinal
lymphadenectomy, as long as I’ve assessed the mediastinum, that
patient has had adequate local therapy, and the patient needs sys-
temic therapy and doesn’t benefit from radiation therapy.
Dr Yang. Just one more comment. We have put in an American
College of Surgeons Oncology Group protocol for small cell. I
hope it will be engaged in about 1 year. We are going to be looking
at this prospectively for patients who do have small cell. They do
receive chemotherapy postoperatively. But I think the more impor-
tant thing will be looking at the translational material, getting the
blood, sputum, and tumor sample so we can learn more about the
disease, which we haven’t had in the past.
DrRobert Cerfolio (Birmingham, Ala). So, Mac, I’m in the op-
erating room. I wedge it out. They call back with small cell. I take
all the N2 nodes and send those for frozen-section, and 2 of them
are positive, microscopic disease. Do I do a lobe or don’t I?
Dr DeCamp. I don’t think you need to do a lobe.546 The Journal of Thoracic and Cardiovascular SurgDr Jack Roth (Houston, Tex). It’s not unusual to see mixed his-
tologies with both small cell and non–small cell components.
Given the time frame of this study and the radiation doses that
were probably used, radiation was likely more effective on the
small cell component and less effective on the non–small cell com-
ponent.What percentage of these patients hadmixed histology, and
how accurate was your histologic evaluation for these patients?
DrDeCamp.Well, anybody who has worked with SEER or any
other database knows that they really want discrete fields. So pa-
tients whowere enteredwere forced to be diagnosedwith a discrete
classification. So within non–small cell, they can be adeno- or
squamous, but when I looked at the data fields, I didn’t see the op-
tion of mixed tumors. We went through and there are a few more
unusual forms, fusiform cell and things like that for small cell.
We eliminated the ‘‘intermediate cell’’ from our analysis because
I thought those were cases on the fence. I think your point is well
taken. Especially if it’s a needle diagnosis for small cell and the pa-
tient doesn’t respond the way you expect, I think those are likely
mixed tumors.ery c September 2011
